No phaseCompleted
RESOLUTE ONYX China RCT Study
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in Comparison With the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
- Sponsor
- Medtronic Vascular (Industry)
- Enrollment
- 550 enrolled
- Conditions
- Ischemic Heart Disease; Stenotic Coronary Lesion; Cardiovascular Diseases; Arteriosclerosis; Coronary Artery Disease
- Interventions
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System; Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Ages
- adults, older adults
- Registry
- NCT03466151
Full record on ClinicalTrials.gov
From the registry
It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary stent system in the treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) in China.
Primary outcomes
- In-stent Late lumen loss measured by quantitative coronary angiography (QCA)
History
Last registry update
Study completion
Primary completion
Started
Registered